HopeStage
Back to all studies
CompletedNCT00314314

Insulin and cognitive performance in people with bipolarity

About this title

The Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder

Read the official source — NCT00314314
Medication studyAges 18–60Canada
The study in practice

Understand this study

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Listed locations
TorontoSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateMay 2006
Recruitment status
Completed
Enrollment listed in the registry
60
Sponsor
University Health Network, Toronto
Sponsor type
University
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
Canada
Age range
From 18 Years to 60 Years
Official registry ID
NCT00314314
Official title
Show the full official title

A Randomized, Double-Blind Controlled Trial Evaluating the Effect of Intranasal Insulin on Neurocognitive Function in Euthymic Patients With Bipolar Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Toronto

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is University Health Network, Toronto, a university.

Did this study involve medication?

Yes. The study involved medication, including Intranasal Insulin and Diluent.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies